|
Disclaimer:
The following information is drawn from materials prepared by
candidates for promotion to full professor. It is intended to illustrate activities and materials that
might support promotion. In
using these materials, please note the following: *The
Provost (and, in some cases, the President) are the University officers
authorized to approve promotions.
All levels of review below these officers are advisory. *Only
Departments are empowered to propose promotions, and the Divisional Dean is
charged with transmitting such proposals to the Provost or returning them to
the Department. *The judgment of the Department, Dean, and Provost will
therefore be critical to assessing qualification for promotion. *Materials
considered by the Department, Dean, and Provost will also (and always)
include confidential evaluations obtained from outside the University. Materials considered by the Provost
will include the confidential evaluations of the Dean and Department, and
those considered by the Dean will include the confidential evaluations of the
Department. *Thus,
the following materials are ONLY PART of a complete proposal for promotion,
whereas promotion is based on the ENTIRE proposal. Therefore, it should not be assumed that a record
comparable to that below will necessarily result in promotion, or that a
record not comparable to that below will fail to result in promotion. The Departmental Chair is likely to
be the best source of advice as to whether promotion is feasible and, when it
is not, what additional activity may result in qualification for promotion. *This
document has been prepared as a tool for use by associate professors in the
Division of the Biological Sciences.
Other individuals who may find it informative are Department Chairmen,
Section Heads, Committee Chairmen, senior faculty and potential recruits. Its intent is to help guide
individuals and their departments as they think about promotion to Professor. This document is not intended to list
the elements that every promotion proposal will be expected to address. The following information is
presented for information purposes only and is not intended to create any
contract or agreement, and its contents are subject to addition, deletion,
and change without prior notice. |
||
|
1.Name: |
Koen van Besien |
|
|
|
Primary Appointment: |
Medicine |
|
Secondary appointments: |
Committee on Immunology |
|
2. Proposed rank: |
PROFESSOR |
|
3. Proposed track: |
CLINICAL SCHOLAR |
LAY SUMMARY:
|
Stem cell transplantation
is a highly complex task involving many specialists. These days it usually consists of
harvesting of the stem cells from the blood of a donor (instead of bone
marrow). The subsequent
harvesting (freezing) of such a product as well as its potential enrichment
with growth factors and eventual readministration of the product to the
patient. Allogeneic
transplantation refers to donation of the cells from someone other than the
patient while autologous transplantation usually describes the preparation of
a cell product from the patient himself. The latter therefore primarily allows for administration
of higher doses of chemotherapy and does not by strict definition consist of
a “transplantation”. Dr. van
Besien’s major contribution has been to reorganize our transplant and
lymphoma program and to more than double its size. He has done so by focusing on several areas of research
interest, in particular the allogeneic transplantation of patients with
lymphoma. This is an interesting
concept in that lymphomas are, to some degree, quite responsive to
chemotherapy. Therefore the
administration of higher doses of chemotherapy in this group of more
chemotherapy-responsive tumors is more successful than it is in more
chemotherapy resistant types of tumors.
However it requires careful management of potential complications and
in the case of allogeneic transplantation “graft vs. host disease
(GVHD)”. Dr. van Besien has
carefully nurtured a team of transplant experts that has expertise in all
aspects of transplantation and in the areas of lymphoma and leukemia
therapy. Together they have
defined an outstanding program within our institution and this was made
possible by Dr. Koen van Besien’s efforts. |
|
MEMBERSHIPS, REVIEW
SECTIONS, EDITORSHIPS Committees
1993-1996: Member,
Harris County Cancer Committee 1997-present: Co-Chairman, Lymphoma
subcommittee, International Bone
Marrow Transplant Registry. The International
Bone Marrow Transplant Registry has access to data provided by transplant
units around the world. Our analysis in lymphoma transplant have defined the
role of allogeneic transplant in lymphoma. 2001-2003: Treasurer,
North-American Autologous Bone Marrow Transplant Registry. 1997-present: Member Transplant
core committee CALGB. 2003-present: Member Medical Advisory Board The
Bone Marrow Foundation 2002-present: Review
Board Leukemia Research Foundation Membership: American Society of
Hematology American Society of
Clinical Oncology Editor: Associate Editor
Leukemia and Lymphoma Leukemia and
Lymphoma is a leading international publication that publishes on clinical
and laboratory research related issues. Member Editorial
Board: Hematología, citocinas, inmunoterapia y terapia cellular Member Editorial
Board: Journal of Clinical Oncology Journal of Clinical
Oncology is the leading Journal for practicing Oncologists (published by
ASCO, the American Society of Clinical Oncology) Ad Hoc reviewer: Blood Leukemia Experimental
Hematology Bone Marrow
Transplantation. Cancer Grant Review
Committees: Leukemia Research
Foundation Dutch Cancer Society
(Fonds voor kankerbestrijding) (Ad Hoc) Honors: Listed in “Best
Doctors in America” |
4. PRESENTATIONS
|
*International
meetings are highlighted with an asterisk 1991:
Participant St Jan’s symposium on Stem cell biology. Az ST Jan, Brugge
Belgium *March
1994:Invited speaker, Keystone
transplant conference (Keystone conference
is the major international transplant conference) May
1994: Invited speaker, Hem/Onc section University of Arkansas, Little Rock,
AR *April
1995: Invited speaker: Jakarta International Cancer Conference, Jakarta,
Indonesia. (International
conference held at the occasion of 50th anniversary of Indonesian
Independence) June
1995: Invited speaker, symposium on progress in transplantation, Emory
University, Atlanta Georgia. July
1995: Invited speaker, University of Antwerp Belgium *March
1996; Participant International workshop on low grade lymphoma, North
Berwick, Scotland (Small
group workshop by invitation with selected speakers from Europe and US) *September
1995: Invited speaker, Symposium on update on Cancer Management,San Juan,
Costa Rica. (Central
American Educational Cancer Conference) September
1996: invited speaker, Symposium on transplantation, University of Gent,
Belgium (Regional
Symposium at the occasion of 10th anniversary of transplant unit) *October
1996, Invited speaker, International Society of experimental hematology,San
Diego, California; *March
1997: IBMTR conferences on bone marrow transplantation (Keystone, CO)
Co-chairman lymphoma committee. March
1997: Invited speaker, symposium on hematological malignancies, Caracas,
Venezuela July
1997: Participant, and invited speaker, Chiron symposium on immunotherapy in
Cancer, San Francisco, CA. September
1997: Invited speaker, North Western University. Hematology/Oncology section October
1997: Invited Speaker Mc Neal Hospital, Berwyn Illinois, Grand Rounds. *February
1998: IBMTR conferences on bone marrow transplantation (Scottsdale, AZ)
Co-chairman lymphoma committee. February
1998: Invited speaker, tumor boards South Suburban Hospital Illinois *March
1998: Invited speaker, International Blood Brain Barrier disruption
symposium, Salishan Lodge, OR. (Small group workshop uniting physicians with
an interest in the management of brain tumors, specifically brain lymphoma) March
1998: Invited Speaker Grand rounds UIC Topic: Allogeneic transplantation in
sickle cell disease. May
1998: Invited speaker Grand rounds, Rush Presbyterian Hospital, Chicago, IL. June
1998: Invited speaker, symposium on progress in transplantation. Ireland
Cancer Center, Cleveland, OH. October
1998: Organizer, symposium progress in allogeneic transplantation, Rockford,
Illinois. *February
1999: IBMTR conferences on bone marrow transplantation (Keystone, CO)
Co-chairman lymphoma committee. *March
1999: Invited Participant, International Blood Brain Barrier disruption
symposium, Salishan Lodge, OR. (Small group workshop uniting physicians with
an interest in the management of brain tumors, specifically brain lymphoma) April
1999: Invited speaker Grand rounds, Woodstock Illinois April
1999: invited speaker, INCA national conference on progress in
transplantation, Rio de Janeiro, Brazil. May
1999: Invited speaker Grand Rounds, Christ Hospital October
1999: invited speaker, International workshop on indolent Lymphoma, Bologna,
Italy. (International
conference uniting international experts) October
1999: Grand rounds Saint Joseph Hospital, Chicago, IL. *January
2000: Invited Participant first international Workshop on non-myeloablative
transplantation. Saint Lucia. (Small group workshop on non-myeloablative
transplantation) *February
2000: IBMTR conferences on bone marrow transplantation (Anaheim,CA)
Co-chairman lymphoma committee. April
2000: Organizer symposium transplantation for Lymphoma, Urbana, Illinois November
2000: Invited speaker Grand rounds, Memorial Sloan Kettering Cancer Center,
NY. January
2001: Invited speaker Grand rounds, Joliet Oncology Associates. *February
2001: IBMTR conferences on bone marrow transplantation (Keystone, Co)
Co-chairman lymphoma committee. June
2001: Hematology/Oncology conference, University of Chicago September
2001: Invited speaker Grand rounds Department of Pediatrics, University of
Chicago September
2001: Ultman Memorial Symposium, University of Chicago Conference Chairman October
2001: Grand Rounds, Department of Medicine, University of Chicago *February
2002: Invited participant Third international workshop on non-myeloablative
stem cell transplantation , Captiva Island, Florida (Small group workshop
on non-myeloablative transplantation) *February
2002: IBMTR conferences on bone marrow transplantation (Orlando, Fl)
Co-chairman lymphoma committee. October
2002: Invited speaker Merrilville Indiana: New antifungals in Hematology November
2002: Invited speaker Brugge
Belgium, Najaarssymposium Hematology December
2002: Invited speaker Section of General Medicine, University of Chicago: *February
2003: IBMTR conferences on bone marrow transplantation (Keystone, Co)
Co-chairman lymphoma committee. September
2003: Invited speaker Grand Rounds Northwestern Memorial Hospital, Chicago,
Illinois. January
2004: Invited speaker St Vincents first Annual Indy Hematology Review,
Indianapolis, Indiana (Regional conference) January
2004: Invited speaker Palos Hospital, Grand Rounds *February
2004: IBMTR conferences on bone marrow transplantation (Orlando, Fl)
Co-chairman lymphoma committee. April
2004: Invited speaker Hematology Grand Rounds, University of Michigan, Ann
Arbor, Michigan August
2004: Invited speaker National Initiative on Lymphoma Education: Hematology
Grand Rounds, Stoneham Massachusetts August
2004: Educational teleconference for ILEX oncology October
2004: National Initiative on Lymphoma Education: Dinner presentation, New
Orleans Louisiana *October
2004: Faculty ,International Symposium : 10 years after the REAL
classification. Bologna Italy. *October
2004: Faculty:11th Biennial Lymphoma Symposium, Cape Town, South
Africa. November
2004: Invited Speaker Hematology Grand Rounds, Cook County Hospital, Chicago. *December
2004: ASH educational Session, Autologous and Allogeneic transplant in low grade lymphoma (The Educational
sessions at ASH are the premier educational event and attended by thousands
of participants.) January
2005: Invited Speaker Grand Rounds, Christ Hospital, Chicago, Illinois *February
2005: IBMTR conferences on bone marrow transplantation (Keystone, Co)
Co-chairman lymphoma committee. |